Organon: Humira A ‘Whole Different Animal’ To Other US Biosimilars
US-Based Firm Also In Discussions To Expand Biosimilar Pipeline
Executive Summary
Shortly after filing for a high-concentration biosimilar adalimumab product with partner Samsung Bioepis, Organon has provided in-depth commentary for its expectations around the impending formation of the market, forecasting a “free for all” six months post-formation.
You may also be interested in...
Teva Confident On US Adalimumab Filing Amid Alvotech Advantages
A delay in FDA approval for partner Alvotech’s proposed high-concentration biosimilar version of Humira has not concerned Teva, especially after the product was approved by the EMA at the end of last year. There “shouldn’t really be any challenges here,” management says.
Coherus Inks $300m Credit Agreement With Ranibizumab Approval Worth $50m
Presenting at the 40th Annual J.P. Morgan Health Care Conference, Coherus BioSciences provided the latest on the firm’s highly-anticipated proposed on-body injector device for pegfilgrastim, days after securing a $300m credit agreement that includes $50m related to the firm’s proposed ranibizumab biosimilar.
Samsung Bioepis Aims To Compete On Higher-Strength Humira In US
Samsung Bioepis and Organon have revealed plans to compete with higher-concentration formulations of adalimumab in the US, after the FDA accepted for review an sBLA for a citrate-free 100mg/ml version of the SB5 Hadlima biosimilar that is already approved in a 50mg/ml formulation.